

White Matter Microstructure Alterations in Early Psychosis and Schizophrenia

Tommaso Pavan¹, Yasser Alemán-Gómez¹, Raoul Jenni², Pascal Steullet², Zoé Schilliger^{2,6}, Daniella Dwir², Martine Cleusix², Luis Alameda^{3,4,5}, Kim Q. Do², Philippe Conus³, Paul Klauser^{2,6}, Patric Hagmann¹ and Ileana Jelescu¹

1. Department of Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL)
2. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne Switzerland
3. Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program. Lausanne University Hospital (CHUV), Lausanne, Switzerland
4. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience. King's College of London, London, UK.
5. Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain.
6. Service of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland

Corresponding author: Tommaso Pavan; address: *Centre de Recherche en Radiologie*, PET3, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland ; telephone:+41213146020; fax:+41213146020; email: tommaso.pavan@chuv.ch

21 **Abstract**

22 Studies on schizophrenia feature diffusion magnetic resonance imaging (dMRI) to investigate white matter (WM)
23 anomalies. The heterogeneity in the possible interpretations of typical Diffusion Tensor Imaging (DTI) metrics
24 highlights the importance of increasing their specificity. Here, we characterize WM pathology in early psychosis (EP)
25 and schizophrenia (SZ) with increased specificity using advanced dMRI: Diffusion Kurtosis Imaging and the
26 biophysical model White Matter Tract Integrity – Watson (WMTI-W). This enables us to better characterize WM
27 abnormalities and relate them to the patient’s clinical characteristics and symptomatology. dMRI-derived
28 microstructure features were extracted from all of WM and from individual tracts in 275 individuals. 93 subjects
29 diagnosed with EP and 47 with SZ were compared respectively to 135 age-range matched healthy controls (HC). The
30 relationships between the microstructure in WM and age at onset, aging trajectories, duration of illness, medication
31 and various clinical scales were investigated in each patient group. WM diffusivities were higher, while kurtosis was
32 lower in EP vs HC and in SZ vs HC. Differences were more pronounced in EP than SZ. WMTI-W model parameters
33 suggest alterations to the extra-axonal compartment in EP and SZ as compared to HC. dMRI patterns in EP and SZ
34 highly suggest WM deterioration in comparison to HC. The microstructure metrics involved point towards extra-
35 axonal alterations, consistent with abnormal myelin integrity and WM deterioration. The direct link to
36 symptomatology is however limited.

37

38 Introduction

39 Psychosis is a psychiatric disorder with heavy implications for the affected individuals, their families, and society¹.
40 However, the disorder etiology remains only partially understood and considered multifactorial, involving a complex
41 interplay of genetic, environmental, and neurobiological factors^{2,3}. Many clinical studies investigating the psychosis
42 spectrum⁴⁻⁹ reported pathological white matter (WM) as a common feature of the disease. Most in vivo studies of
43 WM abnormalities in psychosis use diffusion magnetic resonance imaging (dMRI), an MRI technique that relies on
44 the random motion of water molecules to explore the cellular environment and thus infer the microstructural
45 properties of the underlying biological tissue¹⁰. The most popular dMRI technique in clinical research is Diffusion
46 Tensor Imaging (DTI) and its derived scalar metrics: fractional anisotropy (FA), mean/axial/radial diffusivities
47 (MD/AD/RD). DTI is a so-called *signal representation*¹¹, which means it makes no assumption about the underlying
48 tissue and reports on the apparent diffusivity in the voxel, in any given direction of space¹².

49 In schizophrenia (SZ) and early psychosis (EP), the most frequently reported and accepted dMRI patterns are reduced
50 FA and increased MD^{5,8,13-19}, consistent with a loss of WM integrity and reduced diffusion barriers. Changes are
51 widespread across the WM, with limited spatial consistency between studies^{4,8,13,20}. Such heterogeneity may arise not
52 only from cross-cohort heterogeneity²⁰ but also from different pathological processes affecting the WM, with some
53 tracts showing non-degenerating early maturational shifts, or displaying accelerated aging⁴. Postmortem studies
54 further substantiate the WM involvement found in first-episode psychosis participants³ and in SZ, reporting splitting
55 and decompacting of myelin sheaths together with dystrophic oligodendroglia²¹⁻²⁴ and microglia²⁵.

56 The heterogeneity in the possible DTI interpretations highlights the importance of improving the dMRI-derived
57 microstructure characterization. A first step is to estimate the tissue diffusion properties more thoroughly, e.g. using
58 Diffusion Kurtosis Imaging^{26,27} (DKI), an extension of DTI that is estimated from stronger diffusion-weighting. DKI
59 provides complementary information about tissue heterogeneity by going beyond the Gaussian DTI approximation
60 and quantifying the variance of diffusivities across the voxel, arising from sub-domains such as cellular
61 compartments. DKI has been able to detect widespread WM abnormality²⁸ in regions with complex fiber
62 arrangement²⁹, subtle abnormalities in subjects at high risk for psychosis³⁰ and microstructural connectivity patterns
63 associated to processing speed deficits in SZ³¹.

64 Nevertheless, DTI and DKI metrics are only *sensitive* to features of the tissue microstructure and their changes can be
65 the consequence of several possible pathological mechanisms (**Table 1**). To gain specificity, WM *biophysical models*
66 of diffusion are used¹¹, that capture the diffusion behavior in the underlying tissue with a mathematical model based
67 on *a-priori* knowledge of the tissue structure. WM biophysical models often divide the voxel into two or more
68 compartments, representing water inside and outside the axons, and sometimes the cerebrospinal fluid (CSF)^{11,32}.
69 Models previously used to characterize EP and SZ are free-water imaging³³ (FWI) and Neurite Orientation Dispersion
70 and Density Imaging³⁴ (NODDI). Most FWI studies reported a global increase in free-water in SZ³⁵ and across
71 lifespan³⁶. NODDI detected decreased neurite density and increased orientation dispersion index in first-episode^{37,38}
72 and SZ³⁹. However, both models display limitations in terms of *ad hoc* simplifying assumptions and fit constraints
73 (e.g. in NODDI, all three compartment diffusivities are fixed^{34,40}), strongly limiting the interpretability and validity⁴⁰
74 of the microstructure parameters estimated from the data^{11,41}.

75 In this work we use a more comprehensive biophysical model that overcomes these limitations. White Matter Tract
76 Integrity-Watson^{42,43} (WMTI-W, **Fig. 1**) enables the estimation of intra- and extra-axonal specific diffusivities that are
77 excellent proxies for intra-axonal injury, inflammation and abnormal myelin integrity respectively^{11,43,44}, in addition
78 to axonal density and orientation dispersion. WMTI and WMTI-W have been recently used to characterize WM
79 pathology in a variety of pathological mechanisms (**Table 1**), patient populations⁴⁵ and animal models of disease^{46,47},
80 ranging from Alzheimer's disease⁴⁸⁻⁵⁰ to traumatic brain injury⁵¹, but, to our knowledge, never in schizophrenia.

81 Using WMTI-W, we aim to characterize for the first time WM pathology in EP and SZ with increased specificity, thus
82 overcoming the inconsistencies previously found in EP and SZ literature and relate WM pathology to commonly used
83 clinical measures and characteristics, such as age of psychosis onset, illness duration, medication, and
84 symptomatology. In light of previous post-mortem ultrastructural findings of myelinated fiber pathology (myelin
85 sheath splitting with inclusions of vacuoles, small-axons atrophy, dystrophic oligodendroglia²¹⁻²⁴), we hypothesize
86 that our dMRI findings will be mainly reflected as increased diffusivity of the extra-axonal space and as reduced
87 axonal density.

89 Methods

90 Participants

91 The study was approved by the local Ethics Committee of the Canton of Vaud (CER-VD, Switzerland). Data were
92 collected from 135 healthy controls (HC), 93 subjects with EP and 47 with SZ (**Table 2**). Participants with a diagnosis
93 of EP (within 5 years after a first psychotic episode as defined by the CAARMS⁵²) or SZ (DSM-IV diagnosis of

94 schizophrenia or schizoaffective disorder) were recruited from the Lausanne University Hospital. Exclusion criteria
95 were psychosis related to intoxication, organic brain disease, IQ<70, alcoholism, drug abuse, major somatic disease,
96 or current organic brain damage. Duration of illness, age at psychosis onset and medication were registered. HC were
97 recruited from the same sociodemographic area of the clinical groups and were excluded if they had a first-degree
98 family member who suffered from psychosis or prodromal symptoms, or if they reported current or past
99 antipsychotic treatment. The HC group was further subdivided into younger (HC-Y, n=130, age=26.8±6.8) and older
100 (HC-O, n=84, age=31.9±8.1) to better match the age ranges of the two clinical groups (EP=24.7±5.5; SZ=38.1±9.4
101 years). Within-group individual diagnoses are reported in **Supplementary Table S1**.

102 **MRI acquisition**

104 MRI data were acquired on two different 3-Tesla systems (Magnetom TrioTim and PRISMA, Siemens Healthineers,
105 Erlangen, Germany), each equipped with a 32-channel head coil. A 1-mm isotropic T1-weighted image was acquired
106 for anatomical reference. Whole-brain diffusion-weighted images (DWI) were acquired using diffusion spectrum
107 imaging (DSI) scheme across 15 b-values, ranging from 0 to 8000 s/mm², voxel size of 2.2 x 2.2 x 3 mm³. Further
108 information can be found in the 'Acquisition details' section of the Supplementary Material.

109 **Image preprocessing**

110 The T1-weighted images were bias field corrected⁵³ and skull-stripped via nonlinear registration to the MNI-152
111 template using Advanced Normalization Tools⁵⁴ (ANTs). The diffusion preprocessing pipeline included MP-PCA
112 denoising, Gibbs ringing-, EPI-, eddy current and motion corrections, following most recent guidelines⁵⁵ - see
113 Supplementary Material for preprocessing details.

114 **Microstructure estimation**

116 For DKI and WMTI-W estimation, the diffusion dataset was truncated at $b \leq 2500$ s/mm² (Jensen et al., 2005). DKI was
117 fit voxel-wise⁵⁶ using Matlab, from which seven parameter maps were derived. Four from DTI: RD, MD, AD and FA,
118 and three from DKI: radial, mean, axial kurtosis (RK, MK, AK). Then, WMTI-W model parameters were estimated
119 voxel-wise from the DTI and DKI parameters, using an in-house Python script, yielding other five parameter maps:
120 axonal density f , intra-axonal diffusivity D_a , extra-axonal parallel and perpendicular diffusivities $D_{e||}$, $D_{e\perp}$ and axon
121 orientation alignment c_2 (**Fig. 1**). The WM characterization thus relied on 12 microstructure metrics.

122 **ROI analysis**

124 Individual FA maps were non-linearly registered to the Johns Hopkins University FA template⁵⁷ (JHU) using ANTs,
125 and the WM region-of-interest (ROI) atlas labels were mapped back to individual space. WM ROI definition using the
126 atlas approach was preferred to subject-specific tractography-based reconstruction because it allows easier and
127 more direct comparison with the large body of literature also using the JHU WM atlas. The mean value of each
128 microstructure metric was computed for each ROI, as well as in the whole-WM mask defined as the collection of all
129 JHU ROIs (from here on referred to as 'WM core').

130 **Psychiatric scales**

132 Psychiatric tests included the Global Assessment of Functioning⁵⁸ scale (GAF), the Positive and Negative Syndrome
133 Scale⁵⁹ (PANSS), and the Montgomery-Asberg Depression Rating Scale⁶⁰ (MADRS). For the PANSS, items were
134 categorized using the Wallwork/Fortgang five-factor model⁶¹. PANSS data was not available for 5 EP and 1 SZ subjects,
135 MADRS was not assessed in 6 EP and 16 SZ subjects.

136 **Statistical analysis**

138 Before any statistical analysis, all the microstructure parameter estimates in the WM core and individual JHU ROIs
139 were harmonized for scanner type via ComBat harmonization⁶² that was proven efficient at correcting scanner effects
140 in the same cohort⁶³. Distributions for each metric, ROI and group were tested for normality using the Shapiro-Wilk
141 test and for homogeneity of variance using the Levene's Test. The statistical test used for group comparisons was
142 chosen based on distribution characteristics, resulting in microstructure metrics for the WM core being tested via
143 non-parametric *Wilcoxon* signed-rank test, suitable for non-normal but homogeneous variance distributions. At the
144 ROI level, microstructure metrics between groups were compared using the non-parametric *Brunner-Munzel*^{64,65} test,
145 suitable for distributions with unequal variances. In all comparisons, the estimates were controlled for sex and
146 quadratic age (the model selection procedure for the age correction is detailed in the Supplementary Material). False-
147 Discovery Rate (FDR) correction was applied to control for false positives. In total, 24 tests (12 metrics × 2 group
148 pairs) were conducted for group differences between metrics in the WM core, and 1200 tests for ROI-specific group

149 differences (12 metrics \times 50 JHU ROIs \times 2 group pairs). Effect sizes (r) for each comparison were estimated according
150 to the type of test (*Wilcoxon*: r_w , *Brunner-Munzel*: r_{bm}), see Supplementary Materials for details. The dice coefficient
151 was used to quantify the similarity in ROI alterations across the brain, indicating the proportion (between 0 and 1)
152 of significant alterations that EP and SZ groups have in common.
153 Associations of the microstructure with clinical characteristics: slope contrasts between the various metrics in the
154 WM core and age at first psychosis, duration of illness, and chlorpromazine-equivalent dose (CPZ-equivalent) were
155 estimated in R^{66} . Each regression was corrected for quadratic age and sex, and p-values were FDR corrected. Between-
156 group differences in aging trajectories for the microstructure metrics were estimated in a similar manner, but this
157 time pooling HC vs clinical participants (EP + SZ) and correcting only for sex and FDR.
158 Associations of the microstructure metrics with psychiatric scales: participants with a delay between clinical
159 assessment and MRI scan larger than 45 days were excluded from this analysis to ensure good temporal
160 correspondence between psychiatric status and brain microstructure. The exclusion left 58 EP (mean delay .43 \pm .6
161 months) and 33 SZ (.58 \pm .42 months) available for the analysis. The correlation matrices between WM core metrics
162 and psychiatric scales for EP and SZ were analyzed via hierarchical clustering in R^{66} with the objective of clustering
163 similar relationships between symptoms and WM microstructure. Correlation p-values were FDR-corrected (12
164 metrics \times 8 dimensions \times 2 groups = 192 tests).
165

166 Results

167 Demographics

168 **Table 2** collects cohort demographics. Age was significantly different between clinical participants and controls (i.e.,
169 EP vs HC-Y, $p=0.03$) and SZ vs HC-O, $p<.0001$). Illness duration was longer in SZ than in EP group ($p<.0001$).
170
171

172 Microstructure imaging estimates in the white matter cores

173 Study templates for DTI, DKI and WMTI-W metrics are plotted in **Fig. S2**. The harmonized mean estimates of the WM
174 core for the four groups are reported in **Table S2**. In the WM core, several group differences were found (**Fig. 2**).
175 Compared to HC-Y, EP showed significantly higher DTI diffusivities and lower FA (**Fig. 2A-D**; RD, MD, FA: $p<.0001$, AD:
176 $p=.014$), as well as lower kurtosis (**Fig. 2E-G**; RK: $p=.0017$, MK: $p=.0029$; AK: $p=.035$). Axonal water fraction, f , and
177 alignment, c_2 , in EP were also significantly lower than in HC-Y (**Fig. 2H, L**; f : $p=.0053$ c_2 : $p=.0010$), while extra-axonal
178 diffusivities, $D_{e||}$ and $D_{e\perp}$, were higher (**Fig. 2J, K**; $D_{e||}$: $p=.0010$, $D_{e\perp}$: $p<.0001$). No significant differences were found
179 between EP and HC-Y in terms of intra-axonal diffusivity D_a (**Fig. 2I**). Effect sizes were low to medium with the highest
180 being RD ($r_w=.32$), followed by MD ($r_w=.31$), $D_{e\perp}$ ($r_w=.30$), and FA ($r_w=.29$).
181 Differences between SZ and HC-O were more limited, with no significant DTI metric. Kurtosis, however, was lower in
182 SZ (**Fig. 2E-G**; RK: $p=.035$, MK: $p=.020$, AK: $p=.035$) with a small effect size (average $r_w=.20$). The WMTI-W model
183 revealed reduced f (**Fig. 2H**; $p=.035$), increased D_a (**Fig. 2I**; $p=.017$), and $D_{e||}$ (**Fig. 2J**, $p=.035$). $D_{e||}$ and D_a showed the
184 largest effect size ($r_w=.24$ and $.23$). A complete list of p-values, effect sizes and confidence intervals are found in **Table**
185 **S3**. We found no significant differences between EP and SZ (**Table S4**).
186
187

188 Microstructure imaging estimates of the white matter tracts

189 Group comparison of the JHU ROIs revealed distinct patterns in the microstructure metrics tendencies, highlighting
190 ROI specific alterations in both EP and SZ (**Fig. 3**). Bundles showing the strongest group differences included the
191 corpus callosum (CC), fornix (FX), corona radiata (CR), posterior thalamic radiation (PTR), sagittal stratum (SAGSTR),
192 cingulum (CING/CG) and superior longitudinal fasciculus (SLF). Common features were higher DTI diffusivities in
193 both EP and SZ with respect to their HC groups, with the EP group having the most distinct and widespread increase
194 across the WM. The percentages of WM ROIs with higher RD, MD, and AD were: 56, 54, 18% in EP and 12, 16, 8% in
195 SZ. These differences were generally paired to lower FA of the same ROIs in EP, but not as consistently in SZ (34 vs
196 4%).
197 Kurtosis metrics were lower in both patient groups. In EP, the significantly lower DKI metrics were matched to the
198 increase in DTI metrics except for the bilateral cerebellar peduncle (CP) and CING (hippocampal section acc. JHU)
199 areas. Decreased kurtosis was significant for RK, MK and AK in 24%, 34% and 20% of ROIs, respectively. In SZ, this
200 trend was notably less consistent (RK: 20%, MK: 24%, AK: 12% of ROIs), with some ROIs showing alterations
201 detected by DKI and not DTI, such as the bilateral SAGSTR, the left anterior limb of internal capsule (ALIC) and FX
202 and vice versa, e.g. in CING and right anterior corona radiata (ACR).
203 WMTI-W metrics displayed the same trends as for the whole WM analysis, with f lower in several locations of the WM
204 in SZ and especially EP (10% vs 18% of ROIs), and higher extra-axonal diffusivities. In EP, $D_{e||}$ and $D_{e\perp}$ were
significantly altered in 24 and 20% of the ROIs respectively. In the SZ group, $D_{e||}$ and $D_{e\perp}$ showed fewer number of

205 significant alterations, 16% and 6%. Notably, D_a alterations were uncommon in both groups and not spatially
206 consistent. Finally, sparse c_2 alterations were found in EP (6% of ROIs) but none in SZ.
207 Overall, the Dice coefficient between EP and SZ differences to their respective HC revealed 36% of EP and SZ ROI
208 alterations to be common to both groups. The effects sizes for both groups compared to their HC were on average
209 medium (mean EP $r_{bm}=.48$, SZ $r_{bm}=.50$), with highest effect size found in the FA of the left CP in EP ($r_{bm}=.68$) and the
210 AK of the left SCR in SZ ($r_{bm}=.75$). Kurtosis metrics and FA showed the strongest effect sizes on average across the
211 metrics and ROIs ($r_{bm}\approx.55$). f showed the highest average effect size among the WMTI-W metrics ($r_{bm}=.54$). For
212 additional details about FDR p-values, effect sizes and confidence intervals see **Table S5** and **Table S6**.

213

214 **Association between microstructure estimates and clinical characteristics**

215 We correlated the clinical characteristics to the WM core microstructure (i.e., averaged measure across all WM tracts)
216 because the microstructure metrics showed widespread consistent changes across JHU ROIs in patients.
217 Furthermore, this approach limits considerably the number of statistical tests. There were no significant associations
218 between WM microstructure and age at psychosis onset (**Fig. S3**), nor with illness duration (**Fig. S4**). The intra-axonal
219 diffusivity, D_a , showed significant negative association with CPZ-equivalent dose in the SZ group ($p=.013$), which was
220 significantly different from EP ($p=.0019$, **Fig. S5I**). Notably, $D_{e,||}$, showed similar yet non-significant trends to D_a .
221 Finally, to better understand the aging trajectories of WM microstructure in patients vs. HC we examined the
222 interaction between age and the two grouping variables (EP+SZ) and HC. No significant differences were found after
223 FDR correction (12 tests). Individual age trajectories for each dMRI metric can be found in **Fig. S6**.

224

225 **Association between microstructure estimates and psychopathological symptom domains**

226 We examined associations between microstructure metrics in the WM core and symptom scores. Differences in
227 psychiatric scales between EP and SZ, and the average delay between psychiatric evaluation and MRI scan for the
228 whole cohort are reported in **Table 2**.

229 Overall, correlations between psychiatric scales and WM microstructure metrics were stronger in SZ than EP (**Fig.**
230 **4B vs A**). However, no correlation survived FDR correction (192 tests). In EP, hierarchical clustering identified two
231 macro clusters of microstructure metrics (**Fig. 4A** top dendrograms, clustering of columns): i) diffusivities cluster
232 (RD, MD, AD, $D_{e,||}$, $D_{e,\perp}$, D_a) and ii) kurtosis and anisotropy cluster (RK, AK, MK, f , FA, c_2), informing about the tissue
233 complexity. Contrary to the trends of dMRI group differences between EP vs HC-Y (higher diffusivities and lower
234 kurtosis in the patient vs HC group), GAF score correlated positively with the diffusivities cluster (i) and negatively
235 with the kurtosis cluster (ii). Thus, higher functioning corresponded to faster diffusivities and to lower FA, kurtosis
236 and f . Scores for all the psychiatric dimensions also revealed decreased diffusivities and increased kurtosis with
237 worsening of the symptoms (**Fig. 4A**).

238 In SZ, similar clusters were found for i) diffusivities (RD, MD, AD, $D_{e,||}$, $D_{e,\perp}$), however D_a was clustered with the ii)
239 kurtosis and anisotropy cluster (RK, AK, MK, f , FA, c_2 , D_a , **Fig. 4B**, vertical clustering). The clustering of the symptom
240 dimensions differed from EP. The GAF showed positive correlation with the kurtosis and anisotropy metrics cluster
241 (ii), while negative correlation with the diffusivities cluster (i), consistent with trends in dMRI group differences of
242 elevated diffusivities and reduced kurtosis in SZ vs HC-O. Similarly, PANSS exc. scores correlated with increased
243 diffusivities (i), and decreased complexity (ii, **Fig. 4B**, first horizontal cluster), although these effects should be
244 treated with caution, given the low scores and the absence of acute manic states in the cohort. Finally, a second cluster
245 comprising the rest of the PANSS scales and the MADRS mainly showed consistent negative correlations with D_a and
246 c_2 . Although we underline that none of these associations was significant after FDR, the consistency of positive and
247 negative associations across the scores and cluster blocks suggests they may not be random.

248 **Discussion**

249 With the present analysis we employed more advanced diffusion metrics than DTI, namely DKI and a comprehensive
250 microstructure model, WMTI-W, both aimed at characterizing the WM pathology with increased sensitivity and
251 specificity in EP and SZ cohorts.

252 Our findings reveal that WM alterations are already present and widespread in the EP stage and differences in
253 microstructure are in fact less pronounced between chronic SZ and HC-O when accounting for age. Such results
254 support the developmental interpretation of schizophrenia according to which systematic FA differences to HC
255 originate during adolescence and remain through the lifespan⁶⁷⁻⁷⁰. In this context, the widespread alterations found
256 in EP could result from a shift in peaks in the WM development, achieved earlier in patients^{4,69} than HC. In other
257 words, for a similar age, WM in EP could already have peaked and be on the decline while the HC-Y is still maturing.
258 Consequently, the less widespread differences in SZ vs HC-O could be attributed to the WM maturational shift rather
259 than accelerated aging⁶⁹ for which stronger and more widespread alterations are expected. However, the less

260 pronounced alterations in SZ can also be explained by the SZ cohort size with respect to the wide age range, which
261 could cause the underestimation of the alterations from a statistical perspective. Supporting this last conclusion are
262 the age-trajectories of our cohort that did not significantly differ between EP and SZ participants when compared to
263 HC, while differences in age trajectories between the two stages of the disease are often reported^{4,69,71}.
264 In accordance with our hypothesis, most EP and SZ WM differences to HC concerned the radial direction of diffusion,
265 i.e., perpendicularly to the bundle main axis. Thus, RD and MD were the most affected, while AD differences were less
266 significant. Our study confirms previous DTI^{4,17,67}, dMRI microstructure^{63,72} and post-mortem cytoarchitectural³
267 alterations found already at the EP stage, and the widespread reduced FA and increased MD^{4-6,13-15,17,19,38,67,73}, RD and
268 AD^{6,16,74,75} in areas commonly reported in both EP and chronic SZ.
269 In addition, WM kurtosis was lower for both patient groups, but also more pronounced in EP, and more particularly
270 in the radial direction with a moderate effect size, representing a decrease in tissue complexity and
271 heterogeneity^{26,27,44}. Remarkably, in SZ vs HC-O, DKI was able to identify differences in WM ROIs (SAGSTR, left ALIC
272 and FX) that were not evident in DTI. In a review from Pasternak et al.⁷⁶, all studies but one also reported reduced
273 MK, with one study also reporting lower RK and AK in SZ²⁹.
274 Our ROI-specific differences in microstructure metrics between EP or SZ participants and controls were consistent
275 with literature, as previous studies also reported alterations in CING⁴, FX^{77,78}, CR⁷⁹⁻⁸¹, PTR^{81,82} and SAGSTR⁸² in EP,
276 that remained present in SZ. CC and SLF^{4,15} are considered to have a declining trajectory with aging in SZ^{4,15} (either
277 FA decrease or MD increase when compared to HC), but our results confirm only the SLF trajectory (increased MD,
278 decreased FA in EP and decreased kurtosis in SZ), while the CC was not altered as much in SZ as in EP^{4,77-82}.
279 For the first time, we used WMTI-W, a comprehensive biophysical model of WM, to tease apart possible pathological
280 contributions to the reported WM differences. In EP, WMTI-W helps attribute the observed alterations to the extra-
281 axonal compartment, due to the significant increase in $D_{e,||}$ and $D_{e,\perp}$, but not D_a . The lower axonal water fraction f and
282 orientation coherence c_2 are further consistent with pathological features such as altered myelination and axonal
283 density. The former have indeed been shown to induce an increase in $D_{e,\perp}$ and decrease in f ^{46,47} (**Table 1**) while the
284 increase in $D_{e,||}$ can be a consequence of overall reduced cellular density and thereby hindrance in the extra-axonal
285 space. The SZ group was overall characterized by higher $D_{e,||}$ and lower f , also pointing to less densely packed extra-
286 cellular space. The WM core analysis suggested also higher intra-axonal diffusivity D_a in this group, but only two
287 specific ROIs sustained this trend (CING and CC). Previous works using NODDI³⁴, a comparable but more constrained
288 biophysical model, also reported reduced neurite density (comparable to f) in several ROIs and increased orientation
289 dispersion index (corresponding to lower c_2) in both first episode and chronic SZ⁷². These patterns of preferentially
290 altered extra-axonal environment are also consistent with reports of global increase in "free water" using the FWI
291 technique in SZ cohorts³⁵, although FWI conflates potential pathological mechanisms by defining a tissue
292 compartment (intra- and extra-axonal) vs a free water (CSF) one.
293 The pathological WM changes suggested by WMTI-W are indeed supported by neuroimaging findings beyond dMRI,
294 such as a 14% reduction in WM volume⁸³, and ultrastructural post-mortem studies reporting myelinated WM fiber
295 pathology, such as decompacting and splitting of the myelin sheath, inclusions of vacuoles in-between myelin layers,
296 small-axons atrophy, and the presence of swollen or dystrophic oligodendroglia²²⁻²⁴ and microglia²⁵. In parallel to
297 these morphological changes, a 27-28% reduction in oligodendrocyte densities were reported in cortical layer III and
298 subcortical areas²¹ of SZ specimens.
299 The lack of significant associations of WM microstructure metrics with age at first psychosis, medication or with the
300 duration of illness is aligned with the literature⁸⁴. The correlations between WM microstructure and symptoms were
301 also weak and non-significant, despite in accordance with previous studies⁸. Speculatively, this scenario could be
302 caused by competing pathological mechanisms between deterioration⁴-abnormal myelination⁴⁶ vs
303 neuroinflammation⁴⁴ (demyelination vs microgliosis-astrogliosis in **Table 1**) that have opposite effects on
304 microstructure metrics and, when combined, result in a challenging interpretation. Indeed, neuroinflammation has
305 the effect of reducing diffusivities and increasing kurtosis due to higher cellular crowding associated with
306 microgliosis and astrocytosis^{44,46,47,85}. In support of this mechanism, proinflammatory cytokines have been reported
307 to be elevated in EP⁸⁶ and SZ⁸⁷, and were related to negative symptoms in EP⁸⁶. Furthermore, this interpretation
308 would explain the unconvincing/absence of associations between symptoms and microstructure metrics often
309 reported⁸.
310 Supported by previous postmortem ultrastructural findings, our results point in the direction of pathological
311 myelination and we foresee a motivation to use advanced dMRI for tracking disease progression of this aspect of the
312 pathology, and possibly distinguish myelin loss from axonal loss⁴⁷ or atrophy. However, given the small to medium
313 effect sizes found in most of the microstructure metrics (**Table S3, 5, 6**), their applicability may be limited to group
314 level studies and not at individual level if not assessed in the context of a reference norm (e.g. normative modelling⁸⁸).
315 Several questions also remain open with regards to the evolution of the pathology and how changes to the diffusion
316 metrics behave during acute psychosis phases. Going forward, dMRI combined with careful biophysical modeling
317 could continue to provide crucial information about cellular-level brain changes in EP and SZ in vivo and
318 longitudinally.

319 The first two main limitations of the present study are the use of the age-range approach instead of age-matching and
320 the use of data from two scanners that is a source of bias, possibly even after careful harmonization. The age-range
321 approach was preferred to maintain the sample size as large as possible to better correct for the scanner effect and
322 increase the statistical power of the analyses. In addition, we believe it was preferable not to pair participants by age
323 at the cost of pairing data from different scanners, which could introduce more bias. With regards to the WM
324 biophysical model, the modeling of the axonal dispersion as Watson distribution is not ideally suited for multi-fiber
325 configurations, e.g. crossing fibers¹¹. Furthermore, as symptoms are transitory in nature, the patient's symptomatic
326 state at the time of the MRI scan may differ from the state that led to the assigned clinical score. This mismatch
327 highlights the challenges of relating brain pathology characterized non-invasively using dMRI to symptomatology and
328 the necessity to embrace different approaches to face such heterogeneity (e.g. normative modelling²⁰). In the light of
329 the limitations of the present study, the generalizability of our conclusions needs to be confirmed in other cohorts.
330 In conclusion, with this work we demonstrated that WM alterations, already present at the early psychosis stages,
331 manifest preferentially perpendicular to the axons as major extra-cellular increase in diffusivities, decreased intra-
332 cellular water fraction, and loss of fiber alignment, consistent with early myelin aberrations and shifted maturation.
333 Remarkably, with time, these differences become less dramatic in chronic SZ as compared to age range-matched
334 controls.
335

336 **Acknowledgments**

337 This work was supported by the Swiss National Science Foundation (PCEFP2_194260, to I.J.), the National Center of
338 Competence in Research (NCCR) "SYNAPSY - The Synaptic Bases of Mental Diseases" from the Swiss National Science
339 Foundation (n° 51NF40 - 185897 to KQD & PC) and the Foundation Alamaya. LA is supported by Carigest fellowship.
340 PK, DD and LA are supported by the Adrian & Simone Frutiger Foundation .

341 **Conflict of Interest**

342 The authors have nothing to disclose and there are no conflicts of interest.

343 **References**

- 344 1. Wittchen, H. U. *et al.* The size and burden of mental disorders and other disorders of the brain in Europe 2010.
345 *Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.* **21**, 655–679 (2011).
- 346 2. Keshavan, M. S. *et al.* Neurobiology of early psychosis. *Br. J. Psychiatry* **187**, s8–s18 (2005).
- 347 3. Harrison, P. J. The neuropathology of schizophrenia: A critical review of the data and their interpretation. *Brain*
348 **122**, 593–624 (1999).
- 349 4. Cetin-Karayumak, S. *et al.* White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-
350 site diffusion MRI study. *Mol. Psychiatry* **25**, 3208–3219 (2020).
- 351 5. Friedman, Joseph I. *et al.* Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia
352 Patients. *Am. J. Psychiatry* **165**, 1024–1032 (2008).
- 353 6. Barth, C. *et al.* In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-
354 analysis. *Mol. Psychiatry* **28**, 1159–1169 (2023).
- 355 7. Karlsgodt, K. H. White Matter Microstructure across the Psychosis Spectrum. *Trends Neurosci.* **43**, 406–416
356 (2020).
- 357 8. Kelly, S. *et al.* Widespread white matter microstructural differences in schizophrenia across 4322 individuals:
358 results from the ENIGMA Schizophrenia DTI Working Group. *Mol. Psychiatry* **23**, 1261–1269 (2018).

- 359 9. van Velzen, L. S. *et al.* White matter disturbances in major depressive disorder: a coordinated analysis across
360 20 international cohorts in the ENIGMA MDD working group. *Mol. Psychiatry* **25**, 1511–1525 (2020).
- 361 10. Beaulieu, C. The basis of anisotropic water diffusion in the nervous system - a technical review. *NMR Biomed.*
362 **15**, 435–455 (2002).
- 363 11. Jelescu, I. O. & Budde, M. D. Design and Validation of Diffusion MRI Models of White Matter. *Front. Phys.* **5**,
364 (2017).
- 365 12. Le Bihan, D. *et al.* Diffusion tensor imaging: Concepts and applications. *J. Magn. Reson. Imaging* **13**, 534–546
366 (2001).
- 367 13. Dwork, A. J., Mancevski, B. & Rosoklija, G. White matter and cognitive function in schizophrenia. *Int. J.*
368 *Neuropsychopharmacol.* **10**, 513 (2007).
- 369 14. Pasternak, O., Westin, C.-F., Dahlben, B., Bouix, S. & Kubicki, M. The extent of diffusion MRI markers of
370 neuroinflammation and white matter deterioration in chronic schizophrenia. *Schizophr. Res.* **161**, 113–118
371 (2015).
- 372 15. Waszczuk, K. *et al.* Relationship between White Matter Alterations and Pathophysiological Symptoms in
373 Patients with Ultra-High Risk of Psychosis, First-Episode, and Chronic Schizophrenia. *Brain Sci.* **12**, 354 (2022).
- 374 16. Klauser, P. *et al.* White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically
375 Converge on Brain Network Hubs. *Schizophr. Bull.* **43**, 425–435 (2017).
- 376 17. Tamnes, C. K. & Agartz, I. White Matter Microstructure in Early-Onset Schizophrenia: A Systematic Review of
377 Diffusion Tensor Imaging Studies. *J. Am. Acad. Child Adolesc. Psychiatry* **55**, 269–279 (2016).
- 378 18. Kraguljac, N. V. *et al.* Neuroimaging Biomarkers in Schizophrenia. *Am. J. Psychiatry* **178**, 509–521 (2021).
- 379 19. Sagarwala, R. & Nasrallah, H. A. The effect of antipsychotic medications on white matter integrity in first-
380 episode drug-naïve patients with psychosis: A review of DTI studies. *Asian J. Psychiatry* **61**, 102688 (2021).
- 381 20. Lv, J. *et al.* Individual deviations from normative models of brain structure in a large cross-sectional
382 schizophrenia cohort. *Mol. Psychiatry* **26**, 3512–3523 (2021).
- 383 21. Hof, P. R. *et al.* Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in
384 schizophrenia. *Biol. Psychiatry* **53**, 1075–1085 (2003).
- 385 22. Uranova, N. A., Vikhрева, O. V., Rachmanova, V. I. & Orlovskaya, D. D. Ultrastructural Alterations of Myelinated
386 Fibers and Oligodendrocytes in the Prefrontal Cortex in Schizophrenia: A Postmortem Morphometric Study.
387 *Schizophr. Res. Treat.* **2011**, e325789 (2011).

- 388 23. Uranova, N. A., Vikhрева, O. V., Rakhmanova, V. I. & Orlovskaya, D. D. Ultrastructural pathology of
389 oligodendrocytes adjacent to microglia in prefrontal white matter in schizophrenia. *Npj Schizophr.* **4**, 1–10
390 (2018).
- 391 24. *The Neuropathology of Schizophrenia*. (Springer International Publishing, Cham, 2021). doi:10.1007/978-3-
392 030-68308-5.
- 393 25. Uranova, N. A., Vikhрева, O. V., Rakhmanova, V. I. & Orlovskaya, D. D. Dystrophy of Oligodendrocytes and
394 Adjacent Microglia in Prefrontal Gray Matter in Schizophrenia. *Front. Psychiatry* **11**, (2020).
- 395 26. Jensen, J. H., Helpert, J. A., Ramani, A., Lu, H. & Kaczynski, K. Diffusional kurtosis imaging: The quantification of
396 non-gaussian water diffusion by means of magnetic resonance imaging. *Magn. Reson. Med.* **53**, 1432–1440
397 (2005).
- 398 27. Jensen, J. H. & Helpert, J. A. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. *NMR*
399 *Biomed.* **23**, 698–710 (2010).
- 400 28. Narita, H. *et al.* Mean kurtosis alterations of cerebral white matter in patients with schizophrenia revealed by
401 diffusion kurtosis imaging. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **71**, 169–175 (2016).
- 402 29. Zhu, J. *et al.* Performances of diffusion kurtosis imaging and diffusion tensor imaging in detecting white matter
403 abnormality in schizophrenia. *NeuroImage Clin.* **7**, 170–176 (2015).
- 404 30. Zhang, F. *et al.* MK-Curve improves sensitivity to identify white matter alterations in clinical high risk for
405 psychosis. *NeuroImage* **226**, 117564 (2021).
- 406 31. Kochunov, P. *et al.* Diffusion-weighted imaging uncovers likely sources of processing-speed deficits in
407 schizophrenia. *Proc. Natl. Acad. Sci.* **113**, 13504–13509 (2016).
- 408 32. Novikov, D. S., Fieremans, E., Jespersen, S. N. & Kiselev, V. G. Quantifying brain microstructure with diffusion
409 MRI: Theory and parameter estimation. *NMR Biomed.* **32**, e3998 (2019).
- 410 33. Pasternak, O., Sochen, N., Gur, Y., Intrator, N. & Assaf, Y. Free water elimination and mapping from diffusion MRI.
411 *Magn. Reson. Med.* **62**, 717–730 (2009).
- 412 34. Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: practical in vivo neurite orientation
413 dispersion and density imaging of the human brain. *NeuroImage* **61**, 1000–1016 (2012).
- 414 35. Carreira Figueiredo, I., Borgan, F., Pasternak, O., Turkheimer, F. E. & Howes, O. D. White-matter free-water
415 diffusion MRI in schizophrenia: a systematic review and meta-analysis. *Neuropsychopharmacology* **47**, 1413–
416 1420 (2022).

- 417 36. Cetin-Karayumak, S. *et al.* Characterization of the extracellular free water signal in schizophrenia using multi-
418 site diffusion MRI harmonization. *Mol. Psychiatry* 1–9 (2023) doi:10.1038/s41380-023-02068-1.
- 419 37. Rae, C. L. *et al.* Deficits in Neurite Density Underlie White Matter Structure Abnormalities in First-Episode
420 Psychosis. *Biol. Psychiatry* **82**, 716–725 (2017).
- 421 38. Kraguljac, N. V. *et al.* White matter integrity, duration of untreated psychosis, and antipsychotic treatment
422 response in medication-naïve first-episode psychosis patients. *Mol. Psychiatry* **26**, 5347–5356 (2021).
- 423 39. Kraguljac, N. V. *et al.* A longitudinal neurite and free water imaging study in patients with a schizophrenia
424 spectrum disorder. *Neuropsychopharmacology* **44**, 1932–1939 (2019).
- 425 40. Novikov, D. S., Kiselev, V. G. & Jespersen, S. N. On modeling. *Magn. Reson. Med.* **79**, 3172–3193 (2018).
- 426 41. Jelescu, I. O., Veraart, J., Fieremans, E. & Novikov, D. S. Degeneracy in model parameter estimation for multi-
427 compartmental diffusion in neuronal tissue. *NMR Biomed.* **29**, 33–47 (2016).
- 428 42. Jespersen, S. N., Olesen, J. L., Hansen, B. & Shemesh, N. Diffusion time dependence of microstructural parameters
429 in fixed spinal cord. *NeuroImage* **182**, 329–342 (2018).
- 430 43. Fieremans, E., Jensen, J. H. & Helpert, J. A. White matter characterization with diffusional kurtosis imaging.
431 *NeuroImage* **58**, 177–188 (2011).
- 432 44. Jelescu, I. O. & Fieremans, E. Chapter 2 - Sensitivity and specificity of diffusion MRI to neuroinflammatory
433 processes. in *Advances in Magnetic Resonance Technology and Applications* (eds. Laule, C. & Port, J. D.) vol. 9 31–
434 50 (Academic Press, 2023).
- 435 45. Kamiya, K. *et al.* Diffusion imaging of reversible and irreversible microstructural changes within the
436 corticospinal tract in idiopathic normal pressure hydrocephalus. *NeuroImage Clin.* **14**, 663–671 (2017).
- 437 46. Guglielmetti, C. *et al.* Diffusion kurtosis imaging probes cortical alterations and white matter pathology
438 following cuprizone induced demyelination and spontaneous remyelination. *NeuroImage* **125**, 363–377
439 (2016).
- 440 47. Jelescu, I. O. *et al.* In vivo quantification of demyelination and recovery using compartment-specific diffusion
441 MRI metrics validated by electron microscopy. *NeuroImage* **132**, 104–114 (2016).
- 442 48. Dong, J. W. *et al.* Diffusion MRI biomarkers of white matter microstructure vary nonmonotonically with
443 increasing cerebral amyloid deposition. *Neurobiol. Aging* **89**, 118–128 (2020).
- 444 49. Tristão Pereira, C. *et al.* Synchronous nonmonotonic changes in functional connectivity and white matter
445 integrity in a rat model of sporadic Alzheimer’s disease. *NeuroImage* **225**, 117498 (2021).

- 446 50. Pavan, T. *et al.* Microstructure of White Matter, Probed With Diffusion MRI Modeling, Reveals Distinct
447 Correlations Between Intra- vs Extra-Cellular Spaces and Tau Load. *Alzheimers Dement.* **19**, e078259 (2023).
- 448 51. Chung, S. *et al.* White Matter Tract Integrity: An Indicator of Axonal Pathology after Mild Traumatic Brain Injury.
449 *J. Neurotrauma* **35**, 1015–1020 (2018).
- 450 52. Yung, A. R. *et al.* Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust.*
451 *N. Z. J. Psychiatry* **39**, 964–971 (2005).
- 452 53. Tustison, N. J. *et al.* N4ITK: improved N3 bias correction. *IEEE Trans. Med. Imaging* **29**, 1310–1320 (2010).
- 453 54. Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image registration with cross-
454 correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med. Image Anal.* **12**, 26–41
455 (2008).
- 456 55. Ades-Aron, B. *et al.* Evaluation of the accuracy and precision of the diffusion parameter ESTimation with Gibbs
457 and Noise removal pipeline. *NeuroImage* **183**, 532–543 (2018).
- 458 56. Veraart, J., Sijbers, J., Sunaert, S., Leemans, A. & Jeurissen, B. Weighted linear least squares estimation of
459 diffusion MRI parameters: Strengths, limitations, and pitfalls. *NeuroImage* **81**, 335–346 (2013).
- 460 57. Mori, S., Wakana, S., Van Zijl, P. C. & Nagae-Poetscher, L. M. *MRI Atlas of Human White Matter.* (Elsevier, 2005).
- 461 58. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (4th Ed., Text Rev.)*.
462 (2000).
- 463 59. Kay, S. R., Fiszbein, A. & Opler, L. A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia.
464 *Schizophr. Bull.* **13**, 261–276 (1987).
- 465 60. Montgomery, S. A. & Asberg, M. A new depression scale designed to be sensitive to change. *Br. J. Psychiatry J.*
466 *Ment. Sci.* **134**, 382–389 (1979).
- 467 61. Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D. Searching for a consensus five-
468 factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophr. Res.* **137**, 246–250
469 (2012).
- 470 62. Fortin, J.-P. *et al.* Harmonization of multi-site diffusion tensor imaging data. *NeuroImage* **161**, 149–170 (2017).
- 471 63. Alemán-Gómez, Y. *et al.* Partial-volume modeling reveals reduced gray matter in specific thalamic nuclei early
472 in the time course of psychosis and chronic schizophrenia. *Hum. Brain Mapp.* **41**, 4041–4061 (2020).
- 473 64. Brunner, E. & Munzel, U. The Nonparametric Behrens-Fisher Problem: Asymptotic Theory and a Small-Sample
474 Approximation. *Biom. J.* **42**, 17–25 (2000).

- 475 65. Karch, J. D. Psychologists Should Use Brunner-Munzel's Instead of Mann-Whitney's U Test as the Default
476 Nonparametric Procedure. *Adv. Methods Pract. Psychol. Sci.* **4**, 2515245921999602 (2021).
- 477 66. R Core Team. *R: A Language and Environment for Statistical Computing*. (R Foundation for Statistical Computing,
478 Vienna, Austria, 2023).
- 479 67. Samartzis, L., Dima, D., Fusar-Poli, P. & Kyriakopoulos, M. White Matter Alterations in Early Stages of
480 Schizophrenia: A Systematic Review of Diffusion Tensor Imaging Studies. *J. Neuroimaging* **24**, 101–110 (2014).
- 481 68. Peters, B. D. & Karlsgodt, K. H. White matter development in the early stages of psychosis. *Schizophr. Res.* **161**,
482 61–69 (2015).
- 483 69. Kochunov, P. & Hong, L. E. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter
484 at the center stage. *Schizophr. Bull.* **40**, 721–728 (2014).
- 485 70. Carletti, F. *et al.* Alterations in White Matter Evident Before the Onset of Psychosis. *Schizophr. Bull.* **38**, 1170–
486 1179 (2012).
- 487 71. Cropley, V. L. *et al.* Accelerated Gray and White Matter Deterioration With Age in Schizophrenia. *Am. J. Psychiatry*
488 **174**, 286–295 (2017).
- 489 72. Kraguljac, N. V., Guerreri, M., Strickland, M. J. & Zhang, H. Neurite Orientation Dispersion and Density Imaging
490 in Psychiatric Disorders: A Systematic Literature Review and a Technical Note. *Biol. Psychiatry Glob. Open Sci.*
491 **3**, 10–21 (2023).
- 492 73. Cheung, V. *et al.* Positive symptoms and white matter microstructure in never-medicated first episode
493 schizophrenia. *Psychol. Med.* **41**, 1709–1719 (2011).
- 494 74. Kitamura, H. *et al.* Diffusion tensor analysis in chronic schizophrenia A preliminary study on a high-field (3.0T)
495 system. *Eur. Arch. Psychiatry Clin. Neurosci.* **255**, 313–318 (2005).
- 496 75. Sato, Y. *et al.* Relationship Between White Matter Microstructure and Hallucination Severity in the Early Stages
497 of Psychosis: A Diffusion Tensor Imaging Study. *Schizophr. Bull. Open* **2**, sgab015 (2021).
- 498 76. Pasternak, O., Kelly, S., Sydnor, V. J. & Shenton, M. E. Advances in microstructural diffusion neuroimaging for
499 psychiatric disorders. *NeuroImage* **182**, 259–282 (2018).
- 500 77. Abdul-Rahman, M. F., Qiu, A. & Sim, K. Regionally Specific White Matter Disruptions of Fornix and Cingulum in
501 Schizophrenia. *PLOS ONE* **6**, e18652 (2011).
- 502 78. Luck, D., Malla, A. K., Joobar, R. & Lepage, M. Disrupted integrity of the fornix in first-episode schizophrenia.
503 *Schizophr. Res.* **119**, 61–64 (2010).

- 504 79. Koshiyama, D. *et al.* Role of frontal white matter and corpus callosum on social function in schizophrenia.
505 *Schizophr. Res.* **202**, 180–187 (2018).
- 506 80. Chen, S. *et al.* The role of white matter abnormality in the left anterior corona radiata: In relation to formal
507 thought disorder in patients with schizophrenia. *Psychiatry Res.* **307**, 114302 (2022).
- 508 81. Meng, L. *et al.* Widespread white-matter microstructure integrity reduction in first-episode schizophrenia
509 patients after acute antipsychotic treatment. *Schizophr. Res.* **204**, 238–244 (2019).
- 510 82. Ochi, R. *et al.* White matter microstructural organizations in patients with severe treatment-resistant
511 schizophrenia: A diffusion tensor imaging study. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **100**, 109871
512 (2020).
- 513 83. Elfaki, A. A. *et al.* STEREOLOGICAL EVALUATION OF BRAIN MAGNETIC RESONANCE IMAGES OF
514 SCHIZOPHRENIC PATIENTS. *Image Anal. Stereol.* **32**, 145–153 (2013).
- 515 84. Kanaan, R. *et al.* White matter microstructure in schizophrenia: effects of disorder, duration and medication. *Br.*
516 *J. Psychiatry* **194**, 236–242 (2009).
- 517 85. Wijtenburg, S. A. & Rowland, L. M. Chapter 19 - Schizophrenia spectrum disorders. in *Advances in Magnetic*
518 *Resonance Technology and Applications* (eds. Laule, C. & Port, J. D.) vol. 9 469–487 (Academic Press, 2023).
- 519 86. Dunleavy, C., Elsworth, R. J., Upthegrove, R., Wood, S. J. & Aldred, S. Inflammation in first-episode psychosis:
520 The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and
521 meta-analysis. *Acta Psychiatr. Scand.* **146**, 6–20 (2022).
- 522 87. Goldsmith, D. R., Rapaport, M. H. & Miller, B. J. A meta-analysis of blood cytokine network alterations in
523 psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol. Psychiatry* **21**,
524 1696–1709 (2016).
- 525 88. Marquand, A. *et al.* Conceptualizing mental disorders as deviations from normative functioning. *Mol. Psychiatry*
526 **24**, (2019).
- 527 89. Zhuo, J. *et al.* Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury.
528 *NeuroImage* **59**, 467–477 (2012).
- 529 90. Budde, M. D. & Frank, J. A. Neurite beading is sufficient to decrease the apparent diffusion coefficient after
530 ischemic stroke. *Proc. Natl. Acad. Sci.* **107**, 14472–14477 (2010).
- 531 91. Wang, Y. *et al.* Quantification of increased cellularity during inflammatory demyelination. *Brain* **134**, 3590–
532 3601 (2011).

533 92. Falangola, M. F. *et al.* Histological correlation of diffusional kurtosis and white matter modeling metrics in
534 cuprizone-induced corpus callosum demyelination. *NMR Biomed.* **27**, 948–957 (2014).

535

536 **Figure Legends**

537 **Table 1**

538 Overview of the effect of various pathological processes on diffusion metrics, adapted from ⁴⁴. Astro- and microgliosis
539 reduce water diffusivity and increase kurtosis via increased cellularity. Demyelination on the contrary translates to
540 increased diffusivities and reduced kurtosis. When both are concomitant, they have competing effects. ↑: increase, ↓:
541 decrease, ~: unchanged. Metrics are defined in **Fig.1**.

542 **Figure 1**

543 Schematic of White Matter Tract integrity-Watson (WMTI-W) biophysical model. Axons are modeled as a collection
544 of sticks embedded into an extra-axonal space. Estimated parameters are: axonal water fraction f , intra-axonal
545 diffusivity, D_a , extra-axonal parallel and radial diffusivities, $D_{e||}$ and $D_{e\perp}$, and axonal orientation alignment, c_2 . The
546 latter is derived from the concentration parameter of the Watson distribution, κ and corresponds to $c_2 \equiv \langle \cos^2 \psi \rangle$, with
547 ψ being the angle between axons and the main bundle orientation. c_2 varies between $\frac{1}{3}$, isotropic, and 1, perfectly
548 parallel axons.

549 **Table 2**

550 Cohort demographics. HC amount to 135 Individuals, 79 HC were shared between HC-Y and HC-O. P-values refer to
551 Wilcoxon's tests between clinical and HC groups. χ^2 test is computed for the scanner and sex contingency table. Y:
552 young, O: old, CPZ: chlorpromazine, Delay MRI-Clin. Ass.: difference in months between MRI scan and clinical
553 assessment, SOFAS: Social and Occupational Functioning Assessment Scale, GAF: Global Assessment of Functioning,
554 PANSS: Positive and Negative Syndrome Scale, MADRS: Montgomery-Asberg Depression Rating Scale.

555

556 **Figure 2**

557 Strip plot of the group comparisons. Each clinical group is compared to its respective HC group. *: $p \leq 5e-2$, **: $p \leq 1e-$
558 2 , ***: $p \leq 1e-3$, ****: $p \leq 1e-4$.

559

560 **Figure 3**

561 Heatmaps and brainplots of the JHU ROI group comparison. Top: group comparisons (y-axis right) heatmap of the
562 Brunner-Munzel test significance levels for each dMRI metric (y-axis left) and each region of interest (x-axis). Bottom:
563 brainplots of the same comparisons. The colorbar is shared. Red: clinical group > HC, Blue: clinical group < HC. NS:
564 $p > 0.05$, *: $p \leq 5e-2$, **: $p \leq 1e-2$, ***: $p \leq 1e-3$, ****: $p \leq 1e-4$.

565 *Abbreviations:* L: left; R: right; MIDCP: Middle cerebellar peduncle; PCT: Pontine crossing tract; GCC/BCC/SCC:
566 Genu/Body/Splenium of corpus callosum; ; FX: Fornix (column and body); CST: Corticospinal tract; ML: Medial
567 lemniscus; ICP/SCP: Inferior/Superior cerebellar peduncle; CP: Cerebral peduncle; ALIC/PLIC/RPIC: Anterior
568 limb/Posterior Limb/ Retrolenticular part of internal capsule; ACR/SCR/PCR: Anterior/Superior/Posterior corona
569 radiata; PTR: Posterior thalamic radiation; SAGSTR: Sagittal stratum; EC: External capsule; CING/CG: Cingulum
570 (cingulate gyrus); CING/HIP: Cingulum (hippocampus); FX/STRIA: Fornix (crus) / Stria terminalis ; SLF: Superior
571 longitudinal fasciculus; SFOF/IFOF: Superior/Inferior fronto-occipital fasciculus; IUF: Uncinate fasciculus; TPTM:
572 Tapetum.

573 **Figure 4**

574 Hierarchical clustering of the correlation matrices between WM microstructure estimates and psychopathological
575 symptoms domains. A: EP; B: SZ. Microstructure estimates were corrected for sex and quadratic age. The line
576 diagrams indicate the clustering results. GAF: Global Assessment of Functioning scale; MADRS: Montgomery-Asberg
577 Depression Rating Scale; Positive and Negative Syndrome Scales: pos.: positive; neg.: negative, dis.: disorganized;
578 depr.: depressive; exc.: excited.

579

580

581

582 **Tables**

583 **Table 1**

Cellular process	Proposed changes in signal in DTI and DKI metrics	Validation experiments	Proposed changes in WMTI metrics	Validation experiments
Microgliosis	DTI ↓, DKI ↑	Early stages of the mouse cuprizone intoxication ⁴⁶	$D_a \downarrow, D_{e, } \downarrow, D_{e,\perp} \downarrow$	Early stages of the mouse cuprizone intoxication ⁴⁶
Astrogliosis	DTI ↓, DKI ↑	Mouse traumatic brain injury model ⁸⁹	$D_a \downarrow, D_{e, } \downarrow, D_{e,\perp} \downarrow$	Early stages of the mouse cuprizone intoxication ⁴⁶
Axonal swelling or beading	RD~, MD↓, AD↓↓, RK~, MK↑, AK↑↑	Simulation in synthetic and electron microscopy-derived mouse substrates ^{104,105}	$D_a \downarrow$	Simulation of neurite beading ⁹⁰
Demyelination	RD↑↑, MD↑, AD~, RK↓↓, MK↓, AK~	Cuprizone mouse model ^{46,47,91,92}	$f \downarrow, D_{e, } \uparrow, D_{e,\perp} \uparrow$	Late stages of the mouse cuprizone intoxication ^{46,47,92}
Remyelination	RD↓↓, MD↓, AD~, RK↑↑, MK↑, AK~	Cuprizone mouse model ^{46,47}	$f \uparrow, D_{e, } \downarrow, D_{e,\perp} \downarrow$	Mouse cuprizone intoxication ^{47,*}

*Opposite trends to demyelination were found for the metrics but were non-significant.

584


585 **Table 2**

	HC-Y (N=130)		HC-O (N=84)		EP (N=93)		SZ (N=47)		EP-(HC-Y)	SZ-(HC-O)	EP-SZ
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	p-value	p-value	p-value
Age (years)	26.8	6.8	31.9	8.1	24.7	5.5	38.1	9.4	3.0e-02*	5.6e-05****	p=3.5e-15****
Age at Psychosis Onset (years)					23.0	5.8	23.8	9.3			ns
Duration of illness (months)					16.3	15.5	160.8	77.9			p=1.3e-18****
CPZ-equivalent dose (mg/day)					341.0	274.5	319.6	287.7			ns
Delay MRI-Clin. Ass. (months)	2.5	5.5	3.1	6.9	2.1	3.2	6.6	21.3			p=1.0e-03**
PANSS: total					62.7	15.6	62.0	15.9			ns
PANSS: positive					7.0	2.9	8.3	3.6			p=2.3e-02*
PANSS: negative					14.9	5.7	14.0	5.4			ns
PANSS: disorganized					5.7	2.2	6.5	2.2			p=2.8e-02*
PANSS: excited					6.1	2.2	6.2	2.1			ns
PANSS: depressed					8.2	2.8	8.1	3.3			ns
GAF	83.9	4.4	83.4	4.7	56.2	11.2	56.0	13.2	1.6e-33****	4.6e-16****	ns
MADRS tot.					12.5	8.4	13.2	8.6			ns
		N	Pct.%	N	Pct.	N	Pct.%	N	Pct.%		
Scanner	Prisma	67	51.5	43	51.2	59	63.4	20	42.6	χ^2 :6.3	p=.096 ns
	Trio	63	48.5	41	48.8	34	36.6	27	57.4		
Sex	Female	46	35.4	35	41.7	26	28.0	13	27.7	χ^2 :4.67	p=.19 ns
	Male	84	64.6	49	58.3	67	72.0	34	72.3		

586

587 **Figures**

588 **Figure 1**




Estimated metrics:

$$f, D_a, D_{e,\parallel}, D_{e,\perp}, \langle \cos^2 \psi \rangle \equiv c_2$$

589


590 **Figure 2**



591

592


593 **Figure 3**



594

595

596 **Figure 4**



597